FDA Accepts Unicycive’s Oxylanthanum Carbonate NDA Resubmission
Unicycive Therapeutics said the FDA accepted its resubmitted new drug application for oxylanthanum carbonate and set a PDUFA date of March 25, 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.